{"organizations": [], "uuid": "b55973706ed7097351a5fa8dc3c1d30f86d5efaf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180328.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-prometic-life-sciences-q4-total-re/brief-prometic-life-sciences-q4-total-revenue-6-6-mln-vs-4-1-mln-idUSASC09U4D", "country": "US", "domain_rank": 408, "title": "BRIEF-Prometic Life Sciences Q4 Total Revenue $6.6 Mln Vs $4.1 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.743, "site_type": "news", "published": "2018-03-29T09:11:00.000+03:00", "replies_count": 0, "uuid": "b55973706ed7097351a5fa8dc3c1d30f86d5efaf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-prometic-life-sciences-q4-total-re/brief-prometic-life-sciences-q4-total-revenue-6-6-mln-vs-4-1-mln-idUSASC09U4D", "ord_in_thread": 0, "title": "BRIEF-Prometic Life Sciences Q4 Total Revenue $6.6 Mln Vs $4.1 Mln", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-prometic life sciences", "sentiment": "negative"}, {"name": "prometic life sciences inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC REPORTS ITS Q4-2017 AND YE-2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON ACTIVITIES\n* ‍TOTAL REVENUES FOR Q4 ENDED DECEMBER 31, 2017 WERE $6.6 MILLION COMPARED TO $4.1 MILLION FOR Q4 ENDED DECEMBER 31, 2016​\n* PROMETIC LIFE SCIENCES - ‍RECEIVED FDA INVESTIGATIONAL NEW DRUG (IND) APPROVAL TO COMMENCE ITS PIVOTAL PHASE 3 CLINICAL TRIAL OF PBI-4050 DRUG ​ Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-29T09:11:00.000+03:00", "crawled": "2018-03-29T16:14:06.001+03:00", "highlightTitle": ""}